This story has been updated to reflect that Paxherbal drug was NOT approved by NAFDAC as immune booster against coronavirus. Our extraordinary step in publishing this update is due to the health implications of our earlier story.
Not Approved: NAFDAC denies approving herbal product for COVID-19 treatment
The Director of the Pax Herbal Clinic and Research Laboratories, Ewu in Edo State, Rev. Fr. Anslem Adodo, has reported that the National Agency for Food, Drug Administration and Control (NAFDAC) has finally approved their herbal remedy for the treatment of symptoms associated with COVID-19.
In an internal memo that went viral on social media, Adodo said: “After a series of screening, spanning eight weeks, NAFDAC has today approved our Paxherbal COVID-19 herbal drug, Paxherbal Cugzin, for public use.
“It is the first to be so approved and presently the only one. The drug is specifically for treating the symptoms associated with the coronavirus.”
He said NAFDAC had earlier given tacit approval for the drug to be used, even though the body was yet to make that approval official; hence the initial packs of the herbal remedy bore the disclaimer, “these claims have not yet been verified by NAFDAC.”
But with that hurdle crossed, Paxherbal Cugzin now has the NAFDAC number: A7-4358L.
Pax Herbal Cugzin, which had earlier been produced under the brand name, ‘CVD PLUS,’ before it was rebranded to ‘Paxherbal Cugzin,’ is in capsules and packaged in a container of eighty 290mg capsules, each containing Garcinia Kola, Curcuma Longa and Zingiber officinale.
On April 29, the Pax Herbal Clinic and Research Laboratories released a press statement on its official Facebook page “About Cure For COVID-19,” though the claim was really about the “treatment” of COVID-19.
